The low mutation burden usually seen in EGFR mutant lung cancers is thought to limit antigenicity and immune surveillance, with regulatory T cell-mediated suppression44 or immune exclusion potentially impeding T cell responses further. The gene discussed is EGFR; the disease is lung carcinoma.